Complementary and alternative medicines in management of prostate cancer

A newly published paper in the Journal of Urology has reported on the use of complementary and alternative medicines (CAMs) among a cohort of nearly 8,000 American patients with a diagnosis of prostate cancer between 1996 and 2016. … READ MORE …

Precision medicine and primary Gleason pattern 5 prostate cancer

Patients who are initially diagnosed with primary Gleason pattern 5 localized prostate cancer (i.e., having Gleason scores of 5 + 5 = 10 and 5 + 4 = 9) are well understood to have very high-risk disease. … READ MORE …

Computer modeling, genomics, and prostate cancer prognosis

A newly published paper on the development of prostate cancer in patients of ≤ 55 years of age claims to have shown that

Using a newly-developed computer model, it is now possible to predict the course of the disease in individual patients. … READ MORE …

Experts create guidelines for screening prostate cancer patients for inherited cancer risk genes

Knowing whether you carry inherited cancer risk genes can help you to make the best decisions for your treatment and for your family. … READ MORE …

Commercially available liquid biopsy data may be misleading

A newly published research letter in JAMA Oncology is entitled “Patient-paired sample congruence between 2 commercial liquid biopsy tests”. The two tests are both said — by the companies that market them — to have high clinical sensitivity and specificity in the identification of specific genetic markers associated with high-risk forms of prostate cancer. … READ MORE …

Alternative medicine in the treatment of cancer (prostate cancer included)

There are very few good and thorough clinical studies on the use and the long-term effectiveness or efficacy of alternative forms of medicine in the treatment of cancer (let alone the treatment of prostate cancer specifically). … READ MORE …

How close are we really to “precision medicine” for cancer care?

A newly published paper in the journal JCO Precision Oncology confirms what many of us may have suspected — that the practical application of somatic tissue testing to clinical decision-making was low prior to 2015 . … READ MORE …